Status: Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Participants needed: 645
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Spyre Therapeutics, Inc.Updated: Jun 29, 2026Locations: 243
Eligibility criteria
Diagnosis of UC for ≥3 months before Day 1, confirmed by endoscopy and histology... [+2]
Current diagnosis of Crohn's disease or Inflammatory Bowel Disease (IBD)-Undefin... [+2]